Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

Rhea-AI Summary

Monopar Therapeutics (Nasdaq: MNPR) announced its abstract from the Phase 2 ALXN1840-WD-204 copper balance study was accepted for an oral presentation at AASLD – The Liver Meeting® 2025 in Washington, D.C.

The presentation, titled Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline, is scheduled for Sunday, November 9, 2025, 9:00–9:15 AM EST in the session “Distinct Pathways, Shared Progress: Metabolic/Genetic Disorders & Biliary Physiology.” Presenting author: Aftab Ala, MBBS, M.D., FRCP, Ph.D. The abstract is on the conference website and presentation materials will be posted at www.monopartx.com on November 9, 2025.

WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that its abstract on the Phase 2 ALXN1840-WD-204 copper balance study has been selected for an oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting^® 2025, taking place in Washington, D.C., from November 7-11, 2025.

Presentation Details:

• Title: Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline
• Publication Number: 0073
• Session: Distinct Pathways, Shared Progress: Metabolic/Genetic Disorders & Biliary Physiology
• Date: Sunday, November 9, 9:00-9:15 am EST
• Presenting Author: Aftab Ala, MBBS, M.D., FRCP, Ph.D.
  
  

The abstract is currently available on the conference website, and the materials for the oral presentation will be available at www.monopartx.com on November 9, 2025.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements involve risks and uncertainties including, but not limited to: uncertainties related to the regulatory process that Monopar intends to initiate related to ALXN1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; Monopar’s ability to raise sufficient funds in order for the Company to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Quan Vu
Chief Financial Officer
vu@monopartx.com

Follow Monopar on social media for updates:    
X: @MonoparTx  LinkedIn: Monopar Therapeutics  

FAQ

What will Monopar (MNPR) present at AASLD The Liver Meeting 2025?

Monopar will present an oral abstract on the Phase 2 ALXN1840-WD-204 copper balance study titled Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline.

When and where is Monopar's MNPR oral presentation at AASLD 2025?

The presentation is on Sunday, November 9, 2025, 9:00–9:15 AM EST at AASLD The Liver Meeting® 2025 in Washington, D.C.

Who is the presenting author for Monopar's MNPR AASLD abstract?

The presenting author is Aftab Ala, MBBS, M.D., FRCP, Ph.D.

Where can investors find Monopar (MNPR) presentation materials from AASLD 2025?

Presentation materials will be available at www.monopartx.com on November 9, 2025, and the abstract is on the conference website.

What study is Monopar (MNPR) reporting at the conference and what is its focus?

The company is reporting the Phase 2 ALXN1840-WD-204 study, which focuses on copper balance in Wilson disease patients using tiomolybdate choline.